Which has better valuation & earnings, AMGN or BIIB?

Amgen has higher revenue and earnings than Biogen. Amgen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.62 $7.71B $16.09 23.72 Biogen $9.89B 3.26 $1.29B $5.65 38.60

Is AMGN or BIIB more profitable?

Amgen has a net margin of 22.95% compared to Biogen's net margin of 8.32%. Amgen's return on equity of 124.14% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 22.95% 124.14% 13.18% Biogen 8.32% 11.18% 6.88%

Does the media prefer AMGN or BIIB?

In the previous week, Biogen had 2 more articles in the media than Amgen. MarketBeat recorded 22 mentions for Biogen and 20 mentions for Amgen. Biogen's average media sentiment score of 1.04 beat Amgen's score of 0.39 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 7 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Biogen 9 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or BIIB?

In the previous week, Biogen had 20 more articles in the media than Denali Therapeutics. MarketBeat recorded 22 mentions for Biogen and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.31 beat Biogen's score of 1.04 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 9 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, GILD or BIIB?

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44B 6.35 $8.51B -$2.67 N/A Biogen $9.89B 3.26 $1.29B $5.65 38.60

Is GILD or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Gilead Sciences' net margin of -10.64%. Biogen's return on equity of 11.18% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% Biogen 8.32% 11.18% 6.88%

Does the media prefer GILD or BIIB?

In the previous week, Gilead Sciences had 8 more articles in the media than Biogen. MarketBeat recorded 30 mentions for Gilead Sciences and 22 mentions for Biogen. Biogen's average media sentiment score of 1.04 beat Gilead Sciences' score of 1.02 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 19 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 9 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IONS or BIIB?

In the previous week, Biogen had 16 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 22 mentions for Biogen and 6 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 1.04 beat Ionis Pharmaceuticals' score of 0.30 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Biogen 9 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, MRNA or BIIB?

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $2.21B 28.08 -$2.82B -$7.99 N/A Biogen $9.89B 3.26 $1.29B $5.65 38.60

Is MRNA or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Moderna's net margin of -141.43%. Biogen's return on equity of 11.18% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Biogen 8.32% 11.18% 6.88%

Does the media refer more to MRNA or BIIB?

In the previous week, Moderna had 13 more articles in the media than Biogen. MarketBeat recorded 35 mentions for Moderna and 22 mentions for Biogen. Biogen's average media sentiment score of 1.04 beat Moderna's score of 0.40 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 10 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Biogen 9 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biogen (BIIB) Competitors

$218.32 -0.73 (-0.33%)

As of 10:13 AM Eastern

Compare

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

Should you buy Biogen stock or one of its competitors? Biogen's main competitors and comparable companies include Amgen (AMGN), Denali Therapeutics (DNLI), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biogen compare to Amgen?

Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Amgen has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

Amgen has a net margin of 22.95% compared to Biogen's net margin of 8.32%. Amgen's return on equity of 124.14% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Biogen	8.32%	11.18%	6.88%

76.5% of Amgen shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amgen currently has a consensus target price of $381.32, indicating a potential downside of 0.10%. Biogen has a consensus target price of $230.14, indicating a potential upside of 5.53%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.33
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Amgen has higher revenue and earnings than Biogen. Amgen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.62	$7.71B	$16.09	23.72
Biogen	$9.89B	3.26	$1.29B	$5.65	38.60

In the previous week, Biogen had 2 more articles in the media than Amgen. MarketBeat recorded 22 mentions for Biogen and 20 mentions for Amgen. Biogen's average media sentiment score of 1.04 beat Amgen's score of 0.39 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	7 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Biogen	9 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amgen beats Biogen on 9 of the 16 factors compared between the two stocks.

How does Biogen compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Denali Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Biogen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.56	-$512.54M	-$2.84	N/A
Biogen	$9.89B	3.26	$1.29B	$5.65	38.60

Denali Therapeutics presently has a consensus price target of $35.85, indicating a potential upside of 81.34%. Biogen has a consensus price target of $230.14, indicating a potential upside of 5.53%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biogen has a net margin of 8.32% compared to Denali Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Biogen	8.32%	11.18%	6.88%

In the previous week, Biogen had 20 more articles in the media than Denali Therapeutics. MarketBeat recorded 22 mentions for Biogen and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.31 beat Biogen's score of 1.04 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	9 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Denali Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Biogen compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Gilead Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Gilead Sciences currently has a consensus target price of $158.78, indicating a potential upside of 5.22%. Biogen has a consensus target price of $230.14, indicating a potential upside of 5.53%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.86
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	6.35	$8.51B	-$2.67	N/A
Biogen	$9.89B	3.26	$1.29B	$5.65	38.60

Biogen has a net margin of 8.32% compared to Gilead Sciences' net margin of -10.64%. Biogen's return on equity of 11.18% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Biogen	8.32%	11.18%	6.88%

In the previous week, Gilead Sciences had 8 more articles in the media than Biogen. MarketBeat recorded 30 mentions for Gilead Sciences and 22 mentions for Biogen. Biogen's average media sentiment score of 1.04 beat Gilead Sciences' score of 1.02 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	19 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	9 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gilead Sciences and Biogen tied by winning 8 of the 16 factors compared between the two stocks.

How does Biogen compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Biogen has a net margin of 8.32% compared to Ionis Pharmaceuticals' net margin of -64.76%. Biogen's return on equity of 11.18% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Biogen	8.32%	11.18%	6.88%

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Biogen had 16 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 22 mentions for Biogen and 6 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 1.04 beat Ionis Pharmaceuticals' score of 0.30 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biogen	9 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	8.00	-$381.39M	-$3.46	N/A
Biogen	$9.89B	3.26	$1.29B	$5.65	38.60

Ionis Pharmaceuticals presently has a consensus target price of $90.80, indicating a potential upside of 99.83%. Biogen has a consensus target price of $230.14, indicating a potential upside of 5.53%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Biogen beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Biogen compare to Moderna?

Moderna (NASDAQ:MRNA) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Moderna had 13 more articles in the media than Biogen. MarketBeat recorded 35 mentions for Moderna and 22 mentions for Biogen. Biogen's average media sentiment score of 1.04 beat Moderna's score of 0.40 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biogen	9 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna currently has a consensus target price of $76.72, indicating a potential downside of 50.64%. Biogen has a consensus target price of $230.14, indicating a potential upside of 5.53%. Given Biogen's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

75.3% of Moderna shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.21B	28.08	-$2.82B	-$7.99	N/A
Biogen	$9.89B	3.26	$1.29B	$5.65	38.60

Moderna has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Biogen has a net margin of 8.32% compared to Moderna's net margin of -141.43%. Biogen's return on equity of 11.18% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Biogen	8.32%	11.18%	6.88%

Summary

Biogen beats Moderna on 13 of the 17 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIIB vs. The Competition

Export

Metric	Biogen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.22B	$3.85B	$7.20B	$13.74B
Dividend Yield	N/A	3.65%	2.57%	12.64%
P/E Ratio	38.60	13.92	273.30	25.54
Price / Sales	3.26	1,518.40	676.30	92.31
Price / Cash	9.54	109.14	77.01	51.20
Price / Book	1.75	15.37	10.45	6.31
Net Income	$1.29B	-$22.78M	$3.48B	$357.99M
7 Day Performance	0.43%	-1.00%	0.78%	0.91%
1 Month Performance	2.60%	-1.59%	-0.30%	-2.57%
1 Year Performance	51.65%	36.50%	18.70%	5.07%

Biogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIIB Biogen	3.2361 of 5 stars	$218.08 -0.4%	$230.14 +5.5%	+51.2%	$32.22B	$9.89B	38.60	7,500	Positive News
AMGN Amgen	3.3784 of 5 stars	$437.23 flat	$381.68 -12.7%	+38.2%	$236.38B	$38.10B	27.17	31,500	Analyst Forecast
DNLI Denali Therapeutics	3.7556 of 5 stars	$22.28 flat	$35.85 +60.9%	+54.1%	$3.56B	$330.53M	N/A	430	Positive News
GILD Gilead Sciences	3.5469 of 5 stars	$150.99 flat	$158.04 +4.7%	+34.4%	$187.22B	$30.46B	N/A	17,000	Positive News Ex-Dividend Insider Trade
IONS Ionis Pharmaceuticals	3.0604 of 5 stars	$58.09 flat	$94.20 +62.2%	-23.6%	$9.65B	$944M	N/A	1,402	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIIB) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Competitors

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

How does Biogen compare to Amgen?

Summary

How does Biogen compare to Denali Therapeutics?

Summary

How does Biogen compare to Gilead Sciences?

Summary

How does Biogen compare to Ionis Pharmaceuticals?

Summary

How does Biogen compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB vs. The Competition

Biogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biogen (BIIB) Competitors

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

How does Biogen compare to Amgen?

Which has more risk & volatility, AMGN or BIIB?

Is AMGN or BIIB more profitable?

Do insiders & institutionals have more ownership in AMGN or BIIB?

Do analysts rate AMGN or BIIB?

Which has better valuation & earnings, AMGN or BIIB?

Does the media prefer AMGN or BIIB?

Summary

How does Biogen compare to Denali Therapeutics?

Which has more volatility & risk, DNLI or BIIB?

Which has higher earnings and valuation, DNLI or BIIB?

Do analysts rate DNLI or BIIB?

Do insiders and institutionals have more ownership in DNLI or BIIB?

Is DNLI or BIIB more profitable?

Does the media prefer DNLI or BIIB?

Summary

How does Biogen compare to Gilead Sciences?

Which has more volatility & risk, GILD or BIIB?

Do analysts prefer GILD or BIIB?

Do institutionals & insiders believe in GILD or BIIB?

Which has higher valuation & earnings, GILD or BIIB?

Is GILD or BIIB more profitable?

Does the media prefer GILD or BIIB?

Summary

How does Biogen compare to Ionis Pharmaceuticals?

Is IONS or BIIB more profitable?

Do institutionals & insiders believe in IONS or BIIB?

Does the media refer more to IONS or BIIB?

Which has more risk and volatility, IONS or BIIB?

Which has stronger valuation & earnings, IONS or BIIB?

Do analysts recommend IONS or BIIB?

Summary

How does Biogen compare to Moderna?

Does the media refer more to MRNA or BIIB?

Do analysts prefer MRNA or BIIB?

Do insiders & institutionals believe in MRNA or BIIB?

Which has stronger earnings & valuation, MRNA or BIIB?

Which has more volatility & risk, MRNA or BIIB?

Is MRNA or BIIB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB vs. The Competition

Biogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools